Product Center
23-Valent Pneumococcal Polysaccharide Vaccine
It selects 23 serotypes of pneumococci that are the most widely prevalent and invasive. Advanced manufacturing technologies are adopted to improve antigen purity and enhance safety.
This product completed Phase I clinical trials in April 2023. The Phase I clinical trials showed that this product could trigger a strong immunogenic response (in subjects aged 2 years and above), indicating significant vaccine efficacy. The incidence of vaccination-related adverse events (AE) was lower than that in the control group. After the completion of Phase I clinical trials, the process was further improved and optimized through independent research and development. It is planned to initiate Phase III clinical trials in Q4 2025/Q1 2026.
For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.
- Rrecommend Products
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
